



## Activation of $\alpha$ -secretase by curcumin-aminoacid conjugates

Ramesh B. Narasingapa<sup>a,1</sup>, Manjunatha R. Jargaval<sup>b</sup>, Srinivas Pullabhatla<sup>b</sup>, Htut Htut Htoo<sup>a</sup>, Jagannatha K.S. Rao<sup>c</sup>, Jean-François Hernandez<sup>d</sup>, Piyyarat Govitrapong<sup>a</sup>, Bruno Vincent<sup>a,\*</sup>

<sup>a</sup> Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand

<sup>b</sup> Department of Plantation Products, Spices and Flavour Technology, Central Food Technological Research Institute, Mysore, India

<sup>c</sup> INDICASAT-AIP, City of Knowledge, Panama

<sup>d</sup> Institut des Biomolécules Max Mousseron, UMR5247 CNRS, Universités Montpellier 1 et 2, Faculté de Pharmacie, 15 avenue Charles Flahault, 34093 Montpellier Cedex 5, France

### ARTICLE INFO

#### Article history:

Received 29 June 2012

Available online 13 July 2012

#### Keywords:

Curcumin

Alzheimer

$\beta$ APP

$\alpha$ -Secretase

Disintegrins

Muscarinic receptors

### ABSTRACT

The extracellular senile plaques observed in Alzheimer's disease (AD) patients are mainly composed of amyloid peptides produced from the  $\beta$ -amyloid precursor protein ( $\beta$ APP) by  $\beta$ - and  $\gamma$ -secretases. A third non-amyloidogenic  $\alpha$ -secretase activity performed by the disintegrins ADAM10 and ADAM17 occurs in the middle of the amyloid- $\beta$  peptide A $\beta$  and liberates the large sAPP $\alpha$  neuroprotective fragment. Since the activation of  $\alpha$ -secretase recently emerged as a promising therapeutic approach to treat AD, the identification of natural compounds able to trigger this cleavage is highly required. Here we describe new curcumin-based modified compounds as  $\alpha$ -secretase activators. We established that the aminoacid conjugates curcumin-isoleucine, curcumin-phenylalanine and curcumin-valine promote the constitutive  $\alpha$ -secretase activity and increase ADAM10 immunoreactivity. Strikingly, experiments carried out under conditions mimicking the PKC/muscarinic receptor-regulated pathway display different patterns of activation by these compounds. Altogether, our data identified new lead natural compounds for the future development of powerful and stable  $\alpha$ -secretase activators and established that some of these molecules are able to discriminate between the constitutive and regulated  $\alpha$ -secretase pathways.

© 2012 Elsevier Inc. All rights reserved.

### 1. Introduction

The main component of the senile plaques observed in AD patients is a 40- to 43-amino-acid-long  $\beta$ -amyloid (A $\beta$ ) peptide that is produced from the  $\beta$ -amyloid precursor protein ( $\beta$ APP) through sequential cleavages by  $\beta$ - and  $\gamma$ -secretase [1]. Thus, intense efforts have focused on the development of specific and powerful inhibitors of these activities. However, the fact that both enzymes cleave numerous other physiologically relevant substrates renders their inhibition problematic because of deleterious secondary effects on the nervous system, the immune system and the gastrointestinal tract [2–5]. Therefore, a promising but yet underestimated strategy would be to activate the  $\alpha$ -secretase processing of  $\beta$ APP [6]. This cleavage is performed by the disintegrins ADAM10 and ADAM17 that are responsible for the constitutive and PKC-regulated pathways, respectively [7,8]. Interestingly, this cleavage can be seen as twice beneficial since it both occurs in the middle of

the A $\beta$  sequence and gives rise to the production of the neurotrophic and neuroprotective secreted sAPP $\alpha$  fragment [6]. In addition to protein kinase C (PKC) for which deficits were observed in Alzheimer's disease patients [9], M1/M3 subclass of muscarinic receptors have been shown to be key up-regulators of  $\alpha$ -secretase processing of  $\beta$ APP *in vitro* and *in vivo* [10,11].

Chronic or acute pharmacological stimulations of  $\alpha$ -secretase would engender many deleterious consequences, especially when one considers the tumor-promoting activity of the PKC-activating phorbol esters. The demonstration that the natural compound bryostatin is able, at sub-nanomolar concentrations, to trigger PKC activity, promote sAPP $\alpha$  secretion and reduce A $\beta$  production without inducing tumor represents a step forward in the search of potent and harmless PKC activators [12]. The alternative solution consisting in the activation of  $\alpha$ -secretases themselves, would face a major issue since ADAM10 and ADAM17 target more than 80 different substrates, some of which being implicated in the development of severe pathologies [13]. Thus, it may appear more judicious to privilege the use of long-term and mild treatments, mainly through the consumption of natural compounds present in food. In this context it recently emerged that several natural compounds such as the plant extracts *Ginkgo biloba* and green tea-epigallocatechin-3-gallate can specifically activate the  $\alpha$ -secretase cleavage of  $\beta$ APP [14–15].

Curcumin (diferuloylmethane), the main component extracted from the plant *Curcuma longa* (turmeric), can penetrate the

Abbreviations: PKC, protein kinase C; ADAM, A disintegrin and metalloprotease; PDBu, phorbol-12,13-dibutyrate; PAGE, polyacrylamide gel electrophoresis; ECL, enhanced chemiluminescence; HEK, human embryonic kidney.

\* Corresponding author.

E-mail address: [bruno.vin@mahidol.ac.th](mailto:bruno.vin@mahidol.ac.th) (B. Vincent).

<sup>1</sup> Present address: Center for Nano and Material Sciences, Jain University, Kanakapura Road, Ramanagara District, Karnataka 562112, India.

blood–brain barrier and was suggested as a promising therapy for AD since it displays anti-inflammatory, antioxidant and copper and iron chelation properties [16]. A role for curcumin in the regulation of  $\beta$ APP biology and processing emerged during the past 3 years when curcumin was shown to impair A $\beta$ 42 production, to reduce  $\beta$ APP protein levels, to suppress A $\beta$ -induced BACE1 upregulation and to attenuate  $\beta$ APP maturation in the secretory pathway, thereby decreasing A $\beta$  levels [17,18]. However, the influence of curcumin on the  $\alpha$ -secretase cleavage of  $\beta$ APP has not been investigated so far.

Because of its low absorption, rapid metabolism, inherent instability and hydrophobic nature, clinical trials carried out with curcumin did not show any improvement of cognitive functions in humans with dementia [19]. Therefore, efforts have been made to increase its bioavailability and the use of adjuvants such as piperine ameliorates curcumin stability although no significant improvements were evidenced in mild-to-moderate AD patients [20]. This suggests that further chemical modifications of curcumin are needed to trigger some beneficial effects. In the present study, we examined the effects of curcumin, its metabolite tetrahydrocurcumin (THC) as well as the three amino acid conjugates curcumin–isoleucine, curcumin–phenylalanine and curcumin–valine on the non-amyloidogenic  $\alpha$ -secretase activity. We report that the amino acid conjugates induce the constitutive  $\alpha$ -secretase cleavage of both the synthetic substrate JMV2770 and  $\beta$ APP through an increase in ADAM10 immunoreactivity. Moreover, it appears that these compounds are able to discriminate between the constitutive and the regulated  $\alpha$ -secretase pathways.

## 2. Materials and methods

### 2.1. Antibodies, reagents and cell lines

Polyclonal anti-ADAM10 and anti-ADAM17 were from Millipore. Polyclonal anti- $\beta$ APP (A8717) was from Sigma. Monoclonal anti- $\beta$ -amyloid (DE2B4) which was used to specifically detect sAPP $\alpha$  and monoclonal anti-actin were from Cell Signaling. DMEM complete medium and fetal bovine serum were from Gibco Invitrogen Corporation. Penicillin–streptomycin mix was from PAA. Tris buffer and Glycine were from Vivants. Dimethyl sulfoxide and sodium bicarbonate were from Sigma. Skim milk powder was from Criterion. ECL and ammonium persulfate were from GE Health care. SDS was from Amresco. Metalloprotease inhibitor *o*-phenanthroline was from CalBiochem. The  $\alpha$ -secretase fluorimetric substrate JMV2770 is an 11-amino-acid-long sequence of the cellular prion protein encompassing the peptidyl bond targeted by  $\alpha$ -secretase. JMV2770 (Abz-Thr-Asn-Met-Lys-His-Met-Ala-Gly-Ala-Ala-Gln-EDDnp) contains the ortho-aminobenzoyl (Abz)/dinitro-phenyl (EDDnp) groups as the donor/acceptor and was synthesized as previously described [21]. HEK 293 cells overexpressing ADAM10, ADAM17, M1R and  $\beta$ APP were cultured as previously described [22–25].

### 2.2. Curcumin and curcumin derivatives

Curcumin (~95% purity) was purchased from Ms Spicex chemicals Pvt. Ltd. (Mysore, India). The amino acid conjugates curcumin–isoleucine (Cur-Ile), curcumin–phenylalanine (Cur-Phe) and curcumin–valine (Cur-Val) were prepared on gram scale using the previously described protocol [26] (see Fig. 1 for the detailed structures of the compounds).

### 2.3. Fluorimetric assay on intact cells

HEK293 cells overexpressing ADAM10, ADAM17 or M1R were cultured in 35-mm dishes until cells reach 80% confluency. Cells

were treated in duplicate without (control) or with 50  $\mu$ M curcumin, THC, Cur-Ile, Cur-Phe and Cur-Val for 14 h at 37 °C in DMEM containing 1% FBS. After this treatment period, the PKC activator phorbol-12,13-dibutyrate (PDBu) (1  $\mu$ M, ADAM17-overexpressing cells) or the muscarinic agonist carbachol (100  $\mu$ M, M1R-overexpressing cells) were added for 2 h. Duplicates were then incubated for 30 min at 37 °C either with or without *o*-phenanthroline (100  $\mu$ M in 1.5 ml of PBS). Then, JMV2770 substrate (10  $\mu$ M) was directly added into the media and cells were maintained at 37 °C. After 10, 30 min and subsequently at every 30 min, 100  $\mu$ l of media were removed and fluorescence was recorded in black 96-well plates at 320 and 420 nm excitation and emission wavelengths, respectively. After the last incubation time, cells were resuspended in 10 mM Tris, pH 7.4 and samples were kept for Western blot analysis.

### 2.4. Western blot analyses

Ten micrograms of proteins were loaded onto 8% (ADAM10 and ADAM17) or 10% ( $\beta$ -actin) SDS–PAGE and run at 120 V for 90 min and then transferred onto nitrocellulose membrane for 90 min at 100 V. Patterns of transferred proteins were checked with Ponceau Red staining and nitrocelluloses were incubated in 5% nonfat milk blocking solution for 30 min. Membranes were then incubated with primary antibodies directed against ADAM10 (1/1000 dilution), ADAM17 (1/1000) or  $\beta$ -actin (1/5000) on a platform shaker overnight at 4 °C. After three washes with PBST (PBS containing 0.05% Tween 20), membranes were incubated with HRP-conjugated anti-rabbit (ADAM10 and ADAM17) or anti-mouse ( $\beta$ -actin) secondary antibodies (1/5000) for 2 h and rinsed three times with PBST. Immunoreactivities were processed using ECL and signals were detected using an automatic X-ray developing machine. Films were then analyzed by densitometry and ADAM10 and ADAM17 levels were normalized using  $\beta$ -actin as an internal standard.

### 2.5. Effect of curcumin and its conjugates on $\beta$ APP processing

HEK293 overexpressing  $\beta$ APP were cultured in 35-mm dishes until cells reach 80% confluency. Cells were treated without (control) or with 50  $\mu$ M curcumin and its conjugates THC, Cur-Ile, Cur-Phe and Cur-Val for 14 h at 37 °C in DMEM containing 1% FBS. Media were then removed and replaced with DMEM without FBS and cells were allowed to secrete for 1 h. Both media (20  $\mu$ l, sAPP $\alpha$ ) and cell lysates (20  $\mu$ g of proteins for  $\beta$ APP; 10  $\mu$ g of proteins for  $\beta$ -actin) were submitted to Western blot analysis. Samples were loaded onto 8% (sAPP $\alpha$  and  $\beta$ APP) or 10% ( $\beta$ -actin) SDS–PAGE, run at 120 V for 90 min and transferred onto nitrocellulose membrane for 120 min at 100 V. Nitrocelluloses were incubated in 5% nonfat milk blocking solution for 30 min and incubated with primary antibodies directed against sAPP $\alpha$  (1/500 dilution),  $\beta$ APP (1/5000) or  $\beta$ -actin (1/500) overnight at 4 °C. After three washes with PBST, membranes were incubated with HRP-conjugated anti-rabbit ( $\beta$ APP) or anti-mouse (sAPP $\alpha$  and  $\beta$ -actin) antibodies for 2 h and rinsed three times with PBST. Immunoreactivities were processed using ECL and signals were detected using an automatic X-ray developing machine. Films were then analyzed by densitometry and  $\beta$ APP levels were normalized using  $\beta$ -actin as an internal standard.

### 2.6. Statistical analysis

Statistical analyses were performed with the Prism software (Graphpad, San Diego, USA) by using the Newman–Keuls multiple comparison test for one-way ANOVA and the Student's *t* test for pairwise comparisons. All the results are expressed as mean  $\pm$  SEM values.

Download English Version:

<https://daneshyari.com/en/article/1929065>

Download Persian Version:

<https://daneshyari.com/article/1929065>

[Daneshyari.com](https://daneshyari.com)